NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NEU

NEU - NEUREN PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$11.13

14 Apr
2025

1.940

OPEN

$9.70

21.11%

HIGH

$11.20

1,642,402

LOW

$9.70

TARGET
$25.40 128.2% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NEU: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 111.2 4.3 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx - 10.1% - 96.1% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 255.3 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx111.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx213.2 M
Book Value Per Share xxxxxxxxxxxxxxx286.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-11.3 M
Net Profit Margin xxxxxxxxxxxxxxx66.61 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx49.92 %
Return on Invested Capital xxxxxxxxxxxxxxx49.92 %
Return on Assets xxxxxxxxxxxxxxx43.20 %
Return on Equity xxxxxxxxxxxxxxx49.92 %
Return on Total Capital xxxxxxxxxxxxxxx61.70 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-11.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx222 M
Price To Book Value xxxxxxxxxxxxxxx4.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.00 %
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx38 M
Research & Development xxxxxxxxxxxxxxx33 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

12/03/2025

1

Buy

$20.00

79.69%

Acadia Pharmaceuticals (the commercial partner for Neuren Pharmaceuticals' Daybue product) reported FY24 US sales of US$348m and guided to US$380-405m sales in FY25. This compares with Bell Potter's forecast of US$385m.

The broker notes the US-only guidance implies FY25 royalties of US$41-44m. The analyst notes the company ended FY24 with $359m of pro-forma cash which is enough to fund multiple phase 3 trials for NNZ-2591.

The broker lifted revenue forecasts for FY25-27 on forex impact and cut operating expenses forecasts after factoring in lower R&D, resulting in a rise to FY25-27 earnings estimates.

Target price cut to $20 from $25, and Buy maintained.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 4.30 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 32.50 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

10/03/2025

1

Buy

$28.12

152.65%

Canaccord Genuity notes Neuren Pharmaceuticals' FY24 result was in line with expectations, with the company guiding to FY25 royalty income of $62-67m vs $56.2m in FY25.

Based on Acadia Pharma's result announcement the day prior, the broker sees a slow, linear growth curve as Daybue new patient starts outpace the discontinued ones.

The analyst sees upside from an increase in Rett diagnosis, noting the rise already to 5,800 patients from 5,500.

The broker pushed back milestone payment for the first US$500m sales to FY27. Target price drops marginally to $28.12 from $29.00.

Buy rating remains.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 17.00 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 61.00 cents.
Access Extra Coverage Research History >

NEU STOCK CHART

FNArena News on NEU

1
Australian Broker Call *Extra* Edition – Mar 10, 2025

Mar 10 2025 - Daily Market Reports
2
In Brief: Top Picks In Financials, Retail & Healthcare

Mar 07 2025 - Weekly Reports
3
Next Week At A Glance – 20-24 Jan 2025

Jan 17 2025 - Weekly Reports
4
Rudi’s View: Best Buys & Convictions For 2025

Jan 16 2025 - Rudi's View
5
Rudi’s View: Final Best Buys & Conviction Ideas

Dec 23 2024 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
2
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
3
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
4
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
5
CSL Shares Breaking Free

Jul 23 2024 - Technicals
6
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
7
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
8
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
9
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
10
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps